BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 26, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Oct. 10, 2024

Oct. 10, 2024
Biopharmas raising money in public or private financings, including: Alpha Fusion, Arda, Bio-Path, Cardiol, Clock.bio, Crinetics, Holobiome, Inhibikase, Medigene, Scilex, Rege Nephro, Scholar Rock.
Read More
Glooko platform on desktop, smartphone

Glooko raises $100M, appoints new CEO

Oct. 10, 2024
By Annette Boyle
Glooko Inc. secured a $100 million series F financing to support expansion of its diabetes ecosystem platform, which integrates information from more than 200 devices on a centralized, digital data platform that simplifies care for patients and clinicians. At the same time, the company reported the appointment of Mike Alvarez as CEO.
Read More

Financings for October 10, 2024

Oct. 10, 2024
Med-tech firms raising money in public or private financings, including: Cytovale, Levy Health, Milaboratories, Perimeter Medical Imaging, Rivermark Medical.
Read More
Illustration of kidney with DNA structures
Nephrology

Advancing gene therapy for kidney disease, Purespring adds £80M

Oct. 10, 2024
By Nuala Moran
Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to take a gene therapy for a kidney disease into the clinic. The money enables the company to move the lead program, PS-002, for the treatment of IgA nephropathy to clinical proof of concept and advance programs in other complement-mediated kidney diseases, and in an undisclosed glomerular kidney disease.
Read More
Illustration of kidney with DNA structures

Advancing gene therapy for kidney disease, Purespring adds £80M

Oct. 9, 2024
By Nuala Moran
Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to take a gene therapy for a kidney disease into the clinic. The money enables the company to move the lead program, PS-002, for the treatment of IgA nephropathy to clinical proof of concept and advance programs in other complement-mediated kidney diseases, and in an undisclosed glomerular kidney disease.
Read More

Financings for Oct. 9, 2024

Oct. 9, 2024
Biopharmas raising money in public or private financings, including: City, Orasis, Scholar Rock, Scilex, Somagenetix.
Read More
ShiraTronics

Shiratronics raises $66M for neuromodulation migraine treatment

Oct. 9, 2024
By Annette Boyle
Shiratronics Inc. raised $66 million in an oversubscribed series B financing round to support completion of its recently launched clinical trial to evaluate the safety and efficacy of its neuromodulation device in patients with treatment-resistant chronic migraine.
Read More

Financings for October 9, 2024

Oct. 9, 2024
Med-tech firms raising money in public or private financings, including: Conavi Medical, Titan Medical.
Read More
Immune

Series A financing at Somagenetix to advance gene therapy for chronic granulomatous disease

Oct. 9, 2024
Somagenetix AG has announced the initial closing of its series A financing round, raising CHF10 million.
Read More
Australian coins and bills

Cartherics' AU$15M series B advances CTH-401 for ovarian cancer

Oct. 8, 2024
By Tamra Sami
Immunotherapy company Cartherics Pty Ltd. raised AU$15 million (US$10.3 million) in an oversubscribed series B round that will support the first clinical trial for lead chimeric antigen receptor natural killer therapy CTH-401 for ovarian cancer, and to expand its pipeline to include other diseases.
Read More
Previous 1 2 … 163 164 165 166 167 168 169 170 171 … 686 687 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 21, 2026
  • Red CAR T cell on blue blackground

    To viral or not to viral: In vivo CAR T debates delivery tech

    BioWorld Science
    The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
  • Red CAR T cell on blue blackground

    To viral or not to viral: In vivo CAR T debates delivery tech

    BioWorld Asia
    The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
  • Cell nucleus architecture

    4D Nucleome opens new wave of gene regulation research, discovery

    BioWorld
    After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing